- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06824467
En undersøgelse til evaluering af effektiviteten og sikkerheden af sacituzumab tirumotecan (MK-2870) behandling versus standard for pleje hos deltagere med platinfølsomme tilbagevendende ovariecancer (MK-2870-022/Trofuse-022/Engot-Ov84/GOG-3103)
1. september 2026 opdateret af: Merck Sharp & Dohme LLC
En fase 3, randomiseret, open-label, multicenterundersøgelse for at evaluere effektiviteten og sikkerheden af sacituzumab tirumotecan vedligeholdelsesbehandling med eller uden bevacizumab versus standard for pleje efter anden linje platinbaseret dublet kemoterapi i deltagere med platinfølsom tilbagevendende ovariecancer ( Trofuse-022/Engot-Ov84/GOG-3103)
De vigtigste mål for denne undersøgelse er at lære om sikkerheden ved sacituzumab tirumotecan med bevacizumab, og hvis folk tolererer det; Og hvis folk, der tager sacituzumab tirumotecan med eller uden bevacizumab, lever længere uden at kræft bliver værre end dem, der modtager standard for plejebehandling.
Studieoversigt
Status
Rekruttering
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
770
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studiesteder
-
-
-
CABA, Argentina, C1118AAT
- Rekruttering
- Hospital Aleman ( Site 2903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +541148277000
-
Córdoba, Argentina, 5000
- Rekruttering
- Hospital Italiano de Cordoba ( Site 2908)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +543517078224
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
- Rekruttering
- Instituto Alexander Fleming ( Site 2909)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 5411 3221 8900
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Rekruttering
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 2901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +54 223 496 3224
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1426AAL
- Rekruttering
- Fundación Respirar ( Site 2912)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5491167281601
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000KZE
- Rekruttering
- Instituto de Oncologia de Rosario ( Site 2910)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +543414218909
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2148
- Rekruttering
- Blacktown Hospital ( Site 0211)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61286705071
-
-
Queensland
-
Brisbane, Queensland, Australien, 4120
- Rekruttering
- Gallipoli Medical Research Ltd ( Site 0214)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61733947284
-
-
Victoria
-
East Melbourne, Victoria, Australien, 3002
- Rekruttering
- Epworth Freemasons ( Site 0217)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61385595000
-
Frankston, Victoria, Australien, 3199
- Rekruttering
- Frankston Hospital ( Site 0216)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61409848084
-
-
-
-
-
Namur, Belgien, 5000
- Rekruttering
- CHU UCL Namur/Site Sainte Elisabeth ( Site 0302)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +32 (0)81 70 28 44
-
-
Antwerpen
-
Edegem, Antwerpen, Belgien, 2650
- Rekruttering
- Antwerp University Hospital ( Site 0304)
-
Kontakt:
- Study Coordinator
- Telefonnummer: + 32 3 821 47 19
-
-
Liege
-
Liège, Liege, Belgien, 4000
- Rekruttering
- Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0306)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +32 4 323 5332
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgien, 9000
- Rekruttering
- AZ Sint-Lucas ( Site 0305)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +32 9 224 66 20
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgien, 3000
- Rekruttering
- UZ Leuven ( Site 0301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +32 16 34 74 19
-
-
-
-
-
Rio de Janeiro, Brasilien, 20220-410
- Rekruttering
- Instituto Nacional de Câncer - INCA ( Site 0422)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +552132072985
-
São Paulo, Brasilien, 04014-002
- Rekruttering
- IBCC - Núcleo de Pesquisa e Ensino ( Site 0424)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +551134744264
-
São Paulo, Brasilien, 01321-001
- Rekruttering
- Hospital Paulistano ( Site 0421)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +551130161000
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasilien, 59062-000
- Rekruttering
- Liga Norte Riograndense Contra o Cancer ( Site 0423)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +558440095600
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90610000
- Rekruttering
- Hospital São Lucas da PUCRS ( Site 0425)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +555133203000
-
-
Santa Catarina
-
Lages, Santa Catarina, Brasilien, 88501-001
- Rekruttering
- ANIMI - Unidade de Tratamento Oncologico ( Site 0419)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +554933805200
-
-
São Paulo
-
São José do Rio Preto, São Paulo, Brasilien, 15090-000
- Rekruttering
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0413)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 17 32015054
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Rekruttering
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0512)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 5872315594
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Rekruttering
- Health Sciences North Research Institute ( Site 0517)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 7055237100
-
Mississauga, Ontario, Canada, L5M 2N1
- Rekruttering
- Trillium Health Partners - Credit Valley Hospital ( Site 0508)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 905-813-2200
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Cancer Centre ( Site 0518)
-
Kontakt:
- Study Coordinator
- Telefonnummer: (416) 946-4501
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Rekruttering
- McGill University Health Centre ( Site 0502)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 514-934-1934
-
Montreal, Quebec, Canada, H1T 2M4
- Rekruttering
- CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0505)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 514-252-3400
-
-
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chile, 5507642
- Rekruttering
- Clinica Puerto Montt ( Site 0615)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56961687093
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 8330032
- Rekruttering
- Pontificia Universidad Catolica de Chile ( Site 0611)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56934331806
-
Santiago, Region M. de Santiago, Chile, 8420383
- Rekruttering
- Bradfordhill-Clinical Area ( Site 0610)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56229490970
-
Santiago, Region M. de Santiago, Chile, 7500921
- Rekruttering
- FALP ( Site 0616)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 56224205098
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Rekruttering
- ONCOCENTRO APYS-ACEREY ( Site 0612)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56323320860
-
-
-
-
Bogota D.C.
-
Bogotá, Bogota D.C., Colombia, 110131
- Rekruttering
- FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0806)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +576015948650
-
Bogotá, Bogota D.C., Colombia, 111511
- Rekruttering
- Instituto Nacional De Cancerologia ( Site 0807)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +573154208007
-
-
Risaralda Department
-
Pereira, Risaralda Department, Colombia, 660001
- Rekruttering
- Oncologos Del Occidente ( Site 0805)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +57 3187715522
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Danmark, 2100
- Rekruttering
- Rigshospitalet ( Site 0904)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +45 35453545
-
Herlev, Capital Region, Danmark, 2730
- Rekruttering
- Herlev Hospital ( Site 0903)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +45 38683868
-
-
North Denmark
-
Aalborg, North Denmark, Danmark, 9000
- Rekruttering
- Aalborg Universitetshospital ( Site 0901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 97661400
-
-
Region Syddanmark
-
Vejle, Region Syddanmark, Danmark, 7100
- Rekruttering
- Vejle Sygehus ( Site 0902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 79406088
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B15 2TH
- Rekruttering
- Queen Elizabeth Hospital Birmingham ( Site 2804)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0121 371 8766
-
Leicester, Det Forenede Kongerige, LE1 5WW
- Rekruttering
- Leicester Royal Infirmary ( Site 2808)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0300 303 1573
-
Liverpool, Det Forenede Kongerige, L7 8YA
- Rekruttering
- Clatterbridge Cancer Centre - Liverpool ( Site 2805)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0151 556 5000
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Det Forenede Kongerige, CB2 2QQ
- Rekruttering
- Cambridge University Hospital ( Site 2803)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 01223 216083
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Det Forenede Kongerige, EH4 2XU
- Rekruttering
- Western General Hospital ( Site 2806)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +441315371000
-
-
Lancashire
-
Preston, Lancashire, Det Forenede Kongerige, PR2 9HT
- Rekruttering
- Royal Preston Hospital ( Site 2807)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 01772 524656
-
-
London, City of
-
London, London, City of, Det Forenede Kongerige, SW3 6JJ
- Rekruttering
- ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2801)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 02089156899
-
Sutton, London, City of, Det Forenede Kongerige, SM2 5PT
- Rekruttering
- Royal Marsden Hospital (Sutton) ( Site 2802)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 02089156899
-
-
-
-
North Ostrobothnia
-
Oulu, North Ostrobothnia, Finland, 90220
- Rekruttering
- Oulun yliopistollinen sairaala ( Site 1003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +358505794505
-
-
Northern Savonia
-
Kuopio, Northern Savonia, Finland, 70200
- Rekruttering
- Kuopion Yliopistollinen Sairaala ( Site 1004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +358447174617
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Finland, 33520
- Rekruttering
- Tampereen yliopistollinen sairaala ( Site 1002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +358407274241
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35249
- Rekruttering
- University of Alabama at Birmingham ( Site 0006)
-
Kontakt:
- Study Coordinator
- Telefonnummer: (205) 934-7442
-
-
Alaska
-
Anchorage, Alaska, Forenede Stater, 99508
- Rekruttering
- Alaska Women's Cancer Care ( Site 0096)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 907-562-4673
-
-
California
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- UCSF Medical Center at Mission Bay ( Site 0013)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 415-353-3000
-
Walnut Creek, California, Forenede Stater, 94598
- Rekruttering
- John Muir Health Cancer Center ( Site 0016)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 925-692-5603
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 203-785-5702
-
-
Florida
-
Miami Beach, Florida, Forenede Stater, 33140
- Rekruttering
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0078)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 305-674-2625
-
Sarasota, Florida, Forenede Stater, 34239
- Rekruttering
- Sarasota Memorial Hospital ( Site 0075)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 941-917-2225
-
West Palm Beach, Florida, Forenede Stater, 33401
- Rekruttering
- Florida Cancer Specialists East ( Site 7000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 561-366-4100
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Winship Cancer Institute of Emory University ( Site 0086)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 404-778-1900
-
Augusta, Georgia, Forenede Stater, 30912
- Rekruttering
- Augusta University - Georgia Cancer Center ( Site 0066)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 706-721-6744
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46845
- Rekruttering
- Parkview Research Center at Parkview Regional Medical Center ( Site 0003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 260-425-6981
-
-
Louisiana
-
Covington, Louisiana, Forenede Stater, 70433
- Rekruttering
- Women's Cancer Care ( Site 0067)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 985-892-2252
-
-
Maine
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 207-883-0069
-
-
Minnesota
-
Maplewood, Minnesota, Forenede Stater, 55109
- Rekruttering
- Minnesota Oncology Hematology (MNO) ( Site 8002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 615-693-2574
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Aktiv, ikke rekrutterende
- St. Dominic's Hospital ( Site 0064)
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine ( Site 0052)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 314-454-6215
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Rekruttering
- Nebraska Methodist Hospital ( Site 0053)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 402-354-8534
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 551-996-5855
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Rutgers Cancer Institute of New Jersey ( Site 0071)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 732-235-7258
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87131
- Rekruttering
- University of New Mexico Comprehensive Cancer Center ( Site 0055)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 505-272-4946
-
-
New York
-
Mineola, New York, Forenede Stater, 11501
- Rekruttering
- NYU Langone Hospital - Long Island ( Site 0015)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 516-663-0333
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Laura and Isaac Perlmutter Cancer Center ( Site 0076)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 212-731-6000
-
-
North Carolina
-
Pinehurst, North Carolina, Forenede Stater, 28374
- Rekruttering
- FirstHealth Cancer Center ( Site 0079)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 910-715-8684
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- University of Cincinnati Medical Center ( Site 0090)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 513-584-1958
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 614-293-3300
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74146
- Rekruttering
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 918-505-3200
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Rekruttering
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 541-683-5001
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- Allegheny Health Network West Penn Hospital ( Site 0099)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 412-578-5000
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02905
- Rekruttering
- Women & Infants Hospital ( Site 0050)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 401-274-1100
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Henry-Joyce Cancer Clinic ( Site 0060)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 615-936-8422
-
-
Texas
-
Austin, Texas, Forenede Stater, 78758
- Rekruttering
- Texas Oncology - Central/South Texas ( Site 8009)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 512-873-8900
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Texas Oncology - DFW ( Site 8001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 817-413-1500
-
San Antonio, Texas, Forenede Stater, 78240
- Rekruttering
- Texas Oncology - San Antonio ( Site 8005)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 210-595-5300
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- University Of Texas Health Science Center -San Antonio ( Site 0095)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 210-567-7000
-
Webster, Texas, Forenede Stater, 77598
- Rekruttering
- Texas Oncology - Gulf Coast ( Site 8003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 281-332-7505
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Virginia Cancer Specialists (VCS) ( Site 8011)
-
Kontakt:
- Study Coordinator
- Telefonnummer: (571) 350-8400
-
-
-
-
-
Paris, Frankrig, 75020
- Rekruttering
- Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33 1 44 74 11 53
-
-
Ain
-
Lille, Ain, Frankrig, 59020
- Rekruttering
- Centre Oscar Lambret ( Site 1104)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33320295959
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankrig, 33076
- Rekruttering
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33556333333
-
-
Auvergne-Rhône-Alpes
-
Pierre-Bénite, Auvergne-Rhône-Alpes, Frankrig, 69310
- Rekruttering
- Centre Hopitalier Lyon Sud ( Site 1110)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33478864318
-
-
Calvados
-
Caen, Calvados, Frankrig, 14076
- Rekruttering
- Centre Francois Baclesse ( Site 1108)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33231459700
-
-
Cotes-d Armor
-
Plérin, Cotes-d Armor, Frankrig, 22190
- Rekruttering
- Hôpital Privé Des Côtes d'Armor ( Site 1106)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33257240243
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Frankrig, 31059
- Rekruttering
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1109)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33531155101
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, Frankrig, 37170
- Rekruttering
- Pôle Santé Léonard de Vinci ( Site 1112)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33247602060
-
-
Paris
-
Paris, Paris, Frankrig, 75014
- Rekruttering
- Groupe Hospitalier Broca Cochin Hotel Dieu ( Site 1111)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33158411439
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, Frankrig, 44805
- Rekruttering
- Institut De Cancerologie De L Ouest ( Site 1107)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33 2 40 67 99 00
-
-
Vaucluse
-
Avignon, Vaucluse, Frankrig, 84918
- Rekruttering
- Sainte Catherine Institut du Cancer Avignon Provence ( Site 1105)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33490276161
-
-
-
-
Attica
-
Athens, Attica, Grækenland, 115 28
- Rekruttering
- Aretaieio Hospital ( Site 0701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302107286444
-
Chaïdári, Attica, Grækenland, 12462
- Rekruttering
- ATTIKON GENERAL UNIVERSITY HOSPITAL-Oncology ( Site 0702)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +302105831643
-
-
-
-
-
Dublin, Irland, DO8 NHY1
- Rekruttering
- St James Hospital ( Site 1301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +35314103747
-
-
-
-
-
Hadera, Israel, 3810101
- Rekruttering
- Hillel Yaffe Medical Center ( Site 1404)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +972544512396
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Health Care Campus ( Site 1402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +97247772688
-
Jerusalem, Israel, 9103102
- Rekruttering
- Shaare Zedek Medical Center ( Site 1405)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +97226555424
-
Kfar Saba, Israel, 4428164
- Rekruttering
- Meir Medical Center. ( Site 1403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 972-9-7471575
-
Ramat Gan, Israel, 5265601
- Rekruttering
- Sheba Medical Center ( Site 1401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 972-3-5303157
-
-
-
-
-
Bari, Italien, 70124
- Rekruttering
- Instituto Tumori Giovanni Paolo II ( Site 1505)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390805555355
-
Brescia, Italien, 25124
- Rekruttering
- Istituto Ospedaliero,Fondazione Poliambulanza ( Site 1511)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390303518503
-
Milan, Italien, 20141
- Rekruttering
- Istituto Europeo di Oncologia ( Site 1506)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390257482540
-
Milan, Italien, 20159
- Rekruttering
- Humanitas San Pio X Hospital ( Site 1503)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390269516354
-
Naples, Italien, 80131
- Rekruttering
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1501)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390815903637
-
Padova, Italien, 35128
- Rekruttering
- Istituto Oncologico Veneto IRCCS ( Site 1508)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390498215729
-
Roma, Italien, 00168
- Rekruttering
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 1502)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390630157004
-
Torino, Italien, 10128
- Rekruttering
- Ospedale Mauriziano ( Site 1509)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0115082277
-
-
Friuli Venezia Giulia
-
Aviano, Friuli Venezia Giulia, Italien, 33081
- Rekruttering
- CRO-IRCCS ( Site 1510)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390434659474
-
-
Milano
-
Milan, Milano, Italien, 20133
- Rekruttering
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1507)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 39 0223903479
-
-
Tuscany
-
Pisa, Tuscany, Italien, 56126
- Rekruttering
- Azienda Ospedaliero Universitaria Pisana ( Site 1504)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39050992371
-
-
-
-
-
Fukuoka, Japan, 811-1395
- Rekruttering
- National Hospital Organization Kyushu Cancer Center ( Site 1628)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-92-541-3231
-
Kagoshima, Japan, 890-8760
- Rekruttering
- Kagoshima City Hospital ( Site 1638)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-99-230-7000
-
Niigata, Japan, 951-8566
- Rekruttering
- Niigata Cancer Center Hospital ( Site 1633)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-25-266-5111
-
Osaka, Japan, 541-8567
- Rekruttering
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 1629)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-6-6945-1181
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Rekruttering
- Aichi Cancer Center ( Site 1626)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-52-762-6111
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East ( Site 1641)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-4-7133-1111
-
-
Ehime
-
Matsuyama, Ehime, Japan, 791-0280
- Rekruttering
- National Hospital Organization Shikoku Cancer Center ( Site 1631)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-89-999-1111
-
Tōon, Ehime, Japan, 791-0295
- Rekruttering
- Ehime University Hospital ( Site 1637)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-89-964-5111
-
-
Fukuoka
-
Kurume, Fukuoka, Japan, 830-0011
- Rekruttering
- Kurume University Hospital ( Site 1640)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-942-35-3311
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Rekruttering
- Gunma Prefectural Cancer Center ( Site 1630)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-276-38-0771
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Rekruttering
- Hokkaido University Hospital ( Site 1634)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-11-716-1161
-
-
Iwate
-
Shiwa-gun, Iwate, Japan, 028-3695
- Rekruttering
- Iwate Medical University Hospital ( Site 1635)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-19-613-7111
-
-
Saitama
-
Hidaka, Saitama, Japan, 350-1298
- Rekruttering
- Saitama Medical University International Medical Center ( Site 1632)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-42-984-4111
-
-
Shizuoka
-
Sunto-gun,, Shizuoka, Japan, 411-8777
- Rekruttering
- Shizuoka Cancer Center ( Site 1643)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-55-989-5222
-
-
Tokyo
-
Koto, Tokyo, Japan, 135-8550
- Rekruttering
- Cancer Institute Hospital of JFCR ( Site 1639)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-3-3520-0111
-
Shinjyuku, Tokyo, Japan, 160-8582
- Rekruttering
- Keio University Hospital ( Site 1636)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-3-3353-1211
-
-
-
-
-
Aguascalientes, Mexico, 20124
- Rekruttering
- Centro de Investigación Oncológica Galerías SC ( Site 1720)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525527280926
-
Cuauhtémoc, Mexico, 6100
- Rekruttering
- Cryptex Investigación Clínica S.A. de C.V. ( Site 1715)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525555743589
-
Mexico City, Mexico, 04700
- Rekruttering
- COI Centro Oncologico Internacional S.A.P.I. de C.V. ( Site 1717)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525554248970x4016
-
Oaxaca City, Mexico, 68020
- Rekruttering
- Centro de Investigacion Clinica de Oaxaca ( Site 1714)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +529516035559
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44630
- Rekruttering
- CIO - Centro de Inmuno-Oncología de Occidente ( Site 1719)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +523313587270
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 11819
- Rekruttering
- Higiea Oncologia ( Site 1713)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +525554137773
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64710
- Rekruttering
- I CAN ONCOLOGY CENTER S.A. DE C.V. ( Site 1716)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +528125558165
-
Monterrey, Nuevo León, Mexico, 66220
- Rekruttering
- Servicios de Oncología Médica Integral - Monterrey ( Site 1712)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5218118213989
-
Monterrey, Nuevo León, Mexico, 64460
- Rekruttering
- Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 1711)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +528115443345
-
-
-
-
-
Lima, Peru, 15036
- Rekruttering
- IPOR Instituto Peruano de Oncología & Radioterapia ( Site 3604)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +51 951 881 870
-
Lima, Peru, 15072
- Rekruttering
- Clínica San Felipe ( Site 3603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +5112190000 Ext 8327
-
Lima, Peru, 15038
- Rekruttering
- INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 3601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +51 940 238 282
-
Lima, Peru, 15001
- Rekruttering
- Hospital Guillermo Almenara Irigoyen ( Site 3608)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +51999903343
-
Lima, Peru, 15102
- Rekruttering
- Hospital Cayetano Heredia ( Site 3607)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +51 922 371 048
-
-
Piura
-
Castilla, Piura, Peru, 20001
- Rekruttering
- Unidad de Investigacion Oncologia Clínica Piura ( Site 3606)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +51969618109
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen, 61-848
- Rekruttering
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2106)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48618549049
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Rekruttering
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Site 2101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0048225462295
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-027
- Rekruttering
- Bialostockie Centrum Onkologii ( Site 2104)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0048856646728
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polen, 70-111
- Rekruttering
- Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie ( Site 2103)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +48914661332
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Polen, 25-734
- Rekruttering
- Swietokrzyskie Centrum Onkologii. ( Site 2105)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0048413674128
-
-
-
-
-
Lisbon, Portugal, 1500-650
- Rekruttering
- Hospital da Luz ( Site 3802)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +351217104400
-
Porto, Portugal, 4200-072
- Rekruttering
- Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 3801)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +351225084000
-
-
-
-
-
Bucharest, Rumænien, 011132
- Rekruttering
- Spitalul Clinic Filantropia ( Site 2213)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +40213188930
-
Bucharest, Rumænien, 013975
- Rekruttering
- SC MNT Healthcare Europe SRL ( Site 2218)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +40722927377
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumænien, 400015
- Rekruttering
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2215)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +40264598362
-
-
Dolj
-
Craiova, Dolj, Rumænien, 200746
- Rekruttering
- S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2211)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +40731604432
-
-
Timiș County
-
Timișoara, Timiș County, Rumænien, 300239
- Rekruttering
- Cabinet Medical Oncomed ( Site 2217)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +40256495403
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Hospital Vall D Hebron ( Site 2403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34932746085
-
Barcelona, Spanien, 08907
- Rekruttering
- ICO L Hospitalet ( Site 2408)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34932607744
-
Barcelona, Spanien, 08036
- Rekruttering
- Hospital Clinic I Provincial de Barcelona ( Site 2409)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 34932275402
-
Córdoba, Spanien, 14004
- Rekruttering
- Hospital Universitario Reina Sofia ( Site 2406)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34957011464
-
Madrid, Spanien, 28034
- Rekruttering
- Hospital Ramon y Cajal ( Site 2405)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3491336 82 63
-
Madrid, Spanien, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre ( Site 2411)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34913908626
-
Madrid, Spanien, 28040
- Rekruttering
- Hospital Clinico San Carlos... ( Site 2410)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 34 913303000 x484811
-
Madrid, Spanien, 28046
- Rekruttering
- Hospital Universitario La Paz ( Site 2404)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34 679927508
-
-
Gerona
-
Girona, Gerona, Spanien, 17007
- Rekruttering
- Institut Català d'Oncologia (ICO) - Girona ( Site 2402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34972225828
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28027
- Rekruttering
- Clinica Universidad de Navarra ( Site 2407)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34913531920
-
Madrid, Madrid, Comunidad de, Spanien, 28007
- Rekruttering
- Hospital General Gregorio Maranon de Madrid ( Site 2412)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +34915860860
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spanien, 46010
- Rekruttering
- Hosp Clinico Universitario de Valencia ( Site 2401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 34 961973500
-
-
-
-
-
Seoul, Sydkorea, 03080
- Rekruttering
- Seoul National University Hospital ( Site 2301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82-2-2072-3511
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center ( Site 2303)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82-2-3410-0866
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Sydkorea, 10408
- Rekruttering
- National Cancer Center ( Site 2305)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82-31-920-1760
-
-
Seoul
-
Seodaemun-Gu, Seoul, Sydkorea, 03722
- Rekruttering
- Severance Hospital ( Site 2302)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 82-2-2227-7969
-
Songpa-gu, Seoul, Sydkorea, 05505
- Rekruttering
- Asan Medical Center ( Site 2304)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82-2-3010-3640
-
-
-
-
-
Taichung, Taiwan, 40705
- Rekruttering
- Taichung Veterans General Hospital ( Site 2603)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 886423592525x5822
-
Tainan, Taiwan, 704302
- Rekruttering
- National Cheng Kung University Hospital ( Site 2602)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +88662353535x5222
-
Taipei, Taiwan, 104
- Rekruttering
- Mackay Memorial Hospital ( Site 2604)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886225433535x3941
-
Taipei, Taiwan, 10002
- Rekruttering
- National Taiwan University Hospital ( Site 2601)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 886-223123456x271563
-
Taoyuan, Taiwan, 333
- Rekruttering
- Chang Gung Memorial Hospital - Linkou Branch ( Site 2605)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886-33281200x8258
-
-
-
-
Bangkok
-
Bangkok, Bangkok, Thailand, 10400
- Rekruttering
- Ramathibodi Hospital ( Site 3402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6622011451
-
Bangkok, Bangkok, Thailand, 10700
- Rekruttering
- Faculty of Medicine Siriraj Hospital ( Site 3401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6624194685
-
-
-
-
-
Prague, Tjekkiet, 128 08
- Rekruttering
- Vseobecna fakultni nemocnice v Praze ( Site 3325)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420224967451
-
Prague, Tjekkiet, 150 06
- Rekruttering
- Fakultni nemocnice v Motole ( Site 3322)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420224434749
-
-
Brno-mesto
-
Brno, Brno-mesto, Tjekkiet, 602 00
- Rekruttering
- Fakultni Nemocnice Brno Bohunice ( Site 3324)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 420532233843
-
-
Ostrava Mesto
-
Ostrava-Poruba, Ostrava Mesto, Tjekkiet, 708 52
- Rekruttering
- Fakultni nemocnice Ostrava ( Site 3323)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420597371804
-
-
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Ungarn, 6000
- Rekruttering
- Bacs-Kiskun Megyei Korhaz ( Site 3920)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3676516719
-
-
Csongrád megye
-
Szeged, Csongrád megye, Ungarn, 6720
- Rekruttering
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Onkoterapias Klinika ( Site 3924)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +36 62 544 596
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Rekruttering
- Debreceni Egyetem Klinikai Kozpont ( Site 3922)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0652255705
-
-
Pest County
-
Budapest, Pest County, Ungarn, 1122
- Rekruttering
- Országos Onkológiai Intézet-Ngyógyászat ( Site 3923)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3612248600 Ext 3616
-
Budapest, Pest County, Ungarn, 1088
- Rekruttering
- Semmelweis Egyetem ( Site 3925)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +3612660473/54243
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, Østrig, 1090
- Rekruttering
- Medizinische Universitat Wien ( Site 0102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 004314040061030
-
-
Styria
-
Graz, Styria, Østrig, 8036
- Rekruttering
- Medizinische Universität Graz-Abteilung für Gynäkologie / Onkologie ( Site 0104)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 004331638581081
-
-
Tyrol
-
Innsbruck, Tyrol, Østrig, 6020
- Rekruttering
- Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 0101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 004351250482403
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inkluderingskriterier:
- Har histologisk bekræftet epitelial ovarie, æggeleder eller primær peritoneal karcinom.
- Har modtaget 4 eller flere cyklusser af platinbaseret dublet-kemoterapi i førstelinje og i alt 6 cyklusser af carboplatinbaseret dubletkemoterapi i anden linje om ramme for kræft i æggestokkene (OC).
- Har platin-følsom epiteli OC,
- Har leveret væv af en tumorlæsion, der ikke tidligere var bestrålet
- Human immundefektvirus (HIV) -inficerede deltagere skal have godt kontrolleret HIV på antiretroviral terapi
- Deltagere, der er hepatitis B -overfladeantigen -positiv, er berettigede, hvis de har modtaget hepatitis B -virus (HBV) antiviral terapi i mindst 4 uger, og har ikke påviselig HBV -viral belastning før tildeling (del 1) eller randomisering (del 2)
- Deltagere med en historie med hepatitis C -virus (HCV) -infektion er berettiget, hvis HCV -viral belastning ikke kan påvises ved screening
- Har en ECOG -præstationsstatus på 0 til 1 vurderet inden for 7 dage før allokering (del 1) eller randomisering (del 2)
Ekskluderingskriterier:
- Har ikke-pitheliale kræftformer (kimcelletumorer og kønnorstromale tumorer), grænseoverskridende tumorer (lavt malignt potentiale), slimhinde, seromucinøst, der er overvejende slimhinde, ondartet brenners tumor og udifferentieret karcinom
- Har platin-resistent OC eller platin-ildfast OC
- Har historie med dokumenteret alvorligt tørt øje syndrom, svær meibomisk kirtelsygdom og/eller blepharitis eller hornhindesygdom, der forhindrer/forsinker hornhindeheling.
- Har aktiv inflammatorisk tarmsygdom, der kræver immunsuppressiv medicin eller tidligere historie med inflammatorisk tarmsygdom (f.eks. Crohns sygdom, ulcerøs colitis eller kronisk diarré)
- Har ukontrolleret, signifikant hjerte -kar -sygdom eller cerebrovaskulær sygdom.
- Har en historie med (ikke -infektiøse) pneumonitis/interstitiel lungesygdom, der krævede steroider eller har nuværende pneumonitis/interstitiel lungesygdom.
- HIV-inficerede deltagere med en historie med Kaposis sarkom og/eller multicentriske Castleman's sygdom
- Har modtaget mere end 2 tidligere linjer med systemisk terapi til OC.
- Har modtaget tidligere systemisk anticancerterapi
- Har modtaget tidligere strålebehandling inden for 2 uger efter tildeling (del 1) eller randomisering (del 2) eller har stråling relateret toksicitet, der kræver kortikosteroider
- Har en yderligere malignitet, der skrider frem eller har krævet aktiv behandling inden for de sidste 3 år
- Har aktivt centralnervesystem (CNS) metastaser og/eller kræftfremkaldende meningitis
- Har en aktiv infektion, der kræver systemisk terapi
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Del 1: Sacituzumab tirumotecan + bevacizumab
Deltagerne modtager 4 mg/kg sacituzumab tirumotecan en gang hver 2. uge (Q2W) plus 15 mg/kg bevacizumab en gang hver 3. uge (Q3W) via intravenøs (IV) infusion over 6 uger
|
IV -infusion
Andre navne:
IV -infusion
Andre navne:
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget oralt 2-4 gange dagligt
|
|
Aktiv komparator: Del 2: Standard for pleje (SOC)
Deltagerne modtager lokal standard for pleje indtil progressiv sygdom eller seponering.
Efter lægens skøn modtager deltagerne 15 mg/kg bevacizumab Q3W via IV -infusion indtil progressiv sygdom eller seponering.
|
IV -infusion
Andre navne:
|
|
Eksperimentel: Part 2: Sacituzumab tirumotecan
Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion for up to approximately 2 years or until progressive disease or discontinuation.
At the physician's discretion, participants receive 15 mg/kg of bevacizumab Q3W via IV infusion until progressive disease or discontinuation.
|
IV -infusion
Andre navne:
IV -infusion
Andre navne:
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget pr. Godkendt produktmærke før sacituzumab tirumotecan
Redningsmedicin taget oralt 2-4 gange dagligt
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1: Number of Participants With One or More Adverse Events (AEs)
Tidsramme: Up to 6 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
|
Up to 6 weeks
|
|
Part 1: Number of Participants Who Discontinue Study Intervention Due to an AE
Tidsramme: Up to 6 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
|
Up to 6 weeks
|
|
Part 2: Progression-Free Survival (PFS)
Tidsramme: Up to approximately 4 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first.
Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered PD.
PFS as assessed by blinded independent central review (BICR) will be presented.
|
Up to approximately 4 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 2: Overall Survival (OS)
Tidsramme: Up to approximately 6 years
|
OS is defined as the time from randomization to death due to any cause.
|
Up to approximately 6 years
|
|
Part 2: Number of Participants With One or More AEs
Tidsramme: Up to approximately 4 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
|
Up to approximately 4 years
|
|
Part 2: Number of Participants Who Discontinue Study Intervention Due to an AE
Tidsramme: Up to approximately 4 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
|
Up to approximately 4 years
|
|
Part 2: Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score
Tidsramme: Baseline and up to approximately 4 years
|
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients.
Participant responses to Item 30 (""How would you rate your overall quality of life during the past week?") is scored on a 7-point scale (1=Very Poor to 7=Excellent).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
A higher value indicates a better level of function.
The change from baseline in EORTC QLQ-C30 Item 30 score will be reported.
|
Baseline and up to approximately 4 years
|
|
Part 2: Change From Baseline in EORTC QLQ-C30 Physical Functioning Score
Tidsramme: Baseline and up to approximately 4 years
|
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients.
Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
A higher score indicates a better level of physical functioning.
|
Baseline and up to approximately 4 years
|
|
Part 2: Change From Baseline in EORTC QLQ-C30 Role Functioning Score
Tidsramme: Baseline and up to approximately 4 years
|
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients.
Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?"
and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?"
will be scored on a 4-point scale (1=Not at All to 4=Very Much).
Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.
Higher scores indicate a more impaired level of role functioning.
Change from baseline in the role functioning score will be presented.
|
Baseline and up to approximately 4 years
|
|
Part 2: Change From Baseline in EORTC Quality of Life Questionnaire-Ovarian Cancer Module 28 (QLQ-OV28) abdominal/gastrointestinal (GI) symptom scale
Tidsramme: Baseline and up to approximately 4 years
|
The EORTC QLQ-OV28 is an OC-specific, and psychometrically and clinically validated module to supplement the EORTC QLQ-C30.
The EORTC QLQ-OV28 abdominal/GI symptom scale is scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much).
|
Baseline and up to approximately 4 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Medical Director, Merck Sharp & Dohme LLC
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
9. april 2025
Primær færdiggørelse (Anslået)
27. april 2029
Studieafslutning (Anslået)
9. november 2032
Datoer for studieregistrering
Først indsendt
7. februar 2025
Først indsendt, der opfyldte QC-kriterier
7. februar 2025
Først opslået (Faktiske)
13. februar 2025
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
3. september 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
1. september 2026
Sidst verificeret
1. september 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kønssygdomme, kvindelige
- Neoplasmer i endokrine kirtler
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Æggeledersygdomme
- Ovariale neoplasmer
- Æggelederneoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Histaminmidler
- Neurotransmittermidler
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Polycykliske forbindelser
- Anilider
- Amider
- Anilinforbindelser
- Aminer
- Acetanilider
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Gravideretrioler
- Bevacizumab
- Dexamethason
- Acetaminophen
- Histaminantagonister
- Histamin H2-antagonister
Andre undersøgelses-id-numre
- 2870-022
- 2023 (U.S. NIH-bevilling/kontrakt: GRAMMY Museum Foundation)
- MK-2870-022 (Anden identifikator: MSD)
- TroFuse-022 (Anden identifikator: MSD)
- U1111-1297-4489 (Registry Identifier: UTN)
- GOG-3103 (Anden identifikator: Gynecologic Oncology Group)
- ENGOT-ov84 (Anden identifikator: European Network of Gynaecological Oncological Trial Groups (ENGOT))
- jRCT2031240722 (Registry Identifier: Registry Identifier Japan Registry of Clinical Trials (jRCT))
- 2023-508015-23-00 (Registry Identifier: EU CT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/procedureAccessClinicaltrietaData.pdf
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .